XORTX Therapeutics
XRTX
5 hedge funds and large institutions have $33.2K invested in XORTX Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
0.03% less ownership
Funds ownership: 0.03% → 0% (-0.03%)
17% less funds holding
Funds holding: 6 → 5 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
97% less capital invested
Capital invested by funds: $1.24M → $33.2K (-$1.21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$14.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.3K |
| 3 |
VF
Virtu Financial
New York
|
+$8.04K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$4.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.21M |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$16K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14.7K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$251 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$53 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
1
Two Sigma Securities
New York
| $11.2K | +$14.8K | +59 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $10.1K | +$13.3K | +53 | New |
|
|
VF
3
Virtu Financial
New York
| $6K | +$8.04K | +32 | New |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $4.83K | +$4.27K | +17 | +189% |
|
|
CA
5
Clearstead Advisors
Cleveland,
Ohio
| $1.16K | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
AC
7
Armistice Capital
New York
| – | -$1.21M | -3,686 | Closed |
|
|
8
CIBC World Market
Toronto,
Ontario, Canada
| – | -$16K | -47 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$14.7K | -44 | Closed |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$251 | -1 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$53 | – | – |
|
XRTX Hedge Fund Activity: Q1 2023 in Review
5 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2023, worth a combined $33.2K — down 97% from $1.24M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of XRTX and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $14.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.21M sold.
- 5 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2023, down from 6 in Q4 2022.
- Funds reported $33.2K of XORTX Therapeutics stock for Q1 2023, down 97% quarter-over-quarter.
- 3 funds opened new XORTX Therapeutics positions in Q1 2023 and 4 closed out, a net change of -1 holder.
- The largest XORTX Therapeutics buyer in Q1 2023 was Two Sigma Securities, an estimated $14.8K added.
- The largest XORTX Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $1.21M sold.
Based on aggregated 13F filings for Q1 2023.